Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. IQIRVO (elafibranor)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

IQIRVO (elafibranor)

Medicine - Posted on Feb 13 2025
Active substance (DCI)
  • elafibranor
history (2)
  • 1/29/25

    IQIRVO (elafibranor) - Cholangite biliaire primitive

    Inscription. L'essentiel Avis favorable au remboursement dans le « traitement de la cholangite biliaire primitive (CBP) en a...
    CAV :
    54321
    icône flèche
  • 12/19/24

    IQIRVO (élafibranor) - Cholangite biliaire primitive (CBP)

    Autorisation d’accès précoce refusée à la spécialité IQIRVO (élafibranor) dans l'indication « Traitement de la cholangite bi...
    icône flèche
Technical information
ATC code
  • A05AX06
Manufacturer
IPSEN PHARMA
Presentation

IQIRVO 80 mg, comprimé pelliculé
1 flacon polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimés (CIP : 34009 303 022 2 4)

All our publications
    Drug therapy Liver diseases Pancreatic and biliary tract diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
TuSD8KutCkM5w72Z